. 2021 May;10(5):2470–2477. doi: 10.21037/tcr-21-724

Table 2. Relationship between the expression of Nanog and Fn14 and the pathological parameters of patients with NSCLC.

Pathological parameter	Subgroups	Case (n=89)	Nanog expression, n (%)		χ²	P	Fn14 expression, n (%)		χ²	P
Pathological parameter	Subgroups	Case (n=89)	Positive (n=61)	Negative (n=28)	χ²	P	Positive (n=52)	Negative (n=37)	χ²	P
Gender	Male	47	30 (49.18)	17 (60.71)	1.024	0.311	25 (48.08)	22 (59.46)	1.124	0.289
Gender	Female	42	31 (50.82)	11 (39.29)	1.024	0.311	27 (51.92)	15 (40.54)	1.124	0.289
Age (year)	<60	39	25 (40.98)	14 (50.00)	0.007	0.934	22 (42.31)	17 (45.95)	0.116	0.733
Age (year)	≥60	50	36 (59.02)	14 (50.00)	0.007	0.934	30 (57.69)	20 (54.05)	0.116	0.733
Diameter of tumor (cm)	>5	44	31 (50.82)	12 (42.86)	0.487	0.485	27 (51.92)	17 (45.94)	0.309	0.578
Diameter of tumor (cm)	≤5	45	30 (49.48)	16 (57.14)	0.487	0.485	25 (48.08)	20 (54.05)	0.309	0.578
Differentiated degree	Low	37	30 (49.48)	7 (25.00)	4.620	0.032	31 (59.62)	6 (16.22)	16.763	<0.001
Differentiated degree	Moderate/high	52	31 (50.82)	21 (75.00)	4.620	0.032	21 (40.38)	31 (83.78)	16.763	<0.001
TNM stage	I–II	35	18 (29.51)	17 (60.71)	7.832	0.005	8 (15.38)	27 (72.97)	30.047	<0.001
TNM stage	III–IV	54	43 (70.49)	11 (39.29)	7.832	0.005	44 (54.61)	10 (27.03)	30.047	<0.001
Lymphatic metastasis	Yes	50	41 (67.21)	9 (32.14)	9.588	0.002	39 (75.00)	11 (29.73)	17.996	<0.001
Lymphatic metastasis	No	39	20 (32.79)	19 (67.86)	9.588	0.002	13 (25.00)	26 (70.27)	17.996	<0.001
Histological type	Adenocarcinoma	42	29 (47.54)	13 (46.43)	0.010	0.922	26 (50.00)	16 (43.24)	0.396	0.529
Histological type	Squamous carcinoma	47	32 (52.46)	15 (53.57)	0.010	0.922	26 (50.00)	21 (56.76)	0.396	0.529

NSCLC, non-small cell lung cancer.